Bradykinin inducible receptor is essential to lipopolysaccharide-induced acute lung injury in mice


Autoria(s): CAMPANHOLLE, Gabriela; LANDGRAF, Richardt G.; BORDUCCHI, Erica; SEMEDO, Patricia; WANG, Pamela H. M.; AMANO, Mariane T.; RUSSO, Momtchilo; PACHECO-SILVA, Alvaro; JANCAR, Sonia; CAMARA, Niels O. S.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2010

Resumo

Lipopolysaccharides from gram-negative bacteria are amongst the most common causative agents of acute lung injury, which is characterized by an inflammatory response, with cellular infiltration and the release of mediators/cytokines. There is evidence that bradykinin plays a role in lung inflammation in asthma but in other types of lung inflammation its role is less clear. In the present study we evaluated the role of the bradykinin B(1) receptor in acute lung injury caused by lipopolysaccharide inhalation and the mechanisms behind bradykinin actions participating in the inflammatory response. We found that in C57BI/6 mice, the bradykinin B(1) receptor expression was up-regulated 24 h after lipopolysaccharide inhalation. At this time, the number of cells and protein concentration were significantly increased in the bronchoalveolar lavage fluid and the mice developed airway hyperreactivity to methacholine. In addition, there was an increased expression of tumor necrosis factor-alpha, interleukin-1 beta and interferon-gamma and chemokines (monocytes chemotactic protein-1 and KC) in the bronchoalveolar lavage fluid and in the lung tissue. We then treated the mice with a bradykinin B, receptor antagonist, R-954 (Ac-Orn-[Oic(2), alpha-MePhe(5), D-beta Nal(7), Ile(8)]desArg(9)-bradykinin), 30 min after lipopolysaccharide administration. We observed that this treatment prevented the airway hyperreactivity as well as the increased cellular infiltration and protein content in the bronchoalveolar lavage fluid. Moreover, R-954 inhibited the expression of cytokines/chemokines. These results implicate bradykinin, acting through B(1) receptor, in the development of acute lung injury caused by lipopolysaccharide inhalation. (C) 2010 Elsevier B.V. All rights reserved.

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

INCT Complex Fluids

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[06/06236-2]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[06/03982-5]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[07/07139-3]

Identificador

EUROPEAN JOURNAL OF PHARMACOLOGY, v.634, n.1/Mar, p.132-137, 2010

0014-2999

http://producao.usp.br/handle/BDPI/28683

10.1016/j.ejphar.2010.02.002

http://dx.doi.org/10.1016/j.ejphar.2010.02.002

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

Relação

European Journal of Pharmacology

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #Lipopolysaccharide #Bradykinin #Bradykinin B(1) receptor #Acute lung injury #RESPIRATORY-DISTRESS-SYNDROME #ALVEOLAR MACROPHAGES #REPERFUSION INJURY #B-1 RECEPTORS #PAW EDEMA #ENDOTOXIN #BRONCHOCONSTRICTION #INFLAMMATION #NEUTROPHILS #ANTAGONISTS #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion